December 2015 – AWOCCF grants $60,000 for Research Fellow, Benjamin Farber, for year one of two, to aid in the study of fibrolamellar hepatocellular carcinoma at Rockefeller Research Laboratories, NYC.

December 2015 – AWOCCF grants $240,000 of their $500,000 commitment to MSKCC for the Manufacture and Testing of Humanized 3f8 and Subsequent Research for Phase II Clinical Trials for Neuroblastoma, Osteosarcoma and Other Pediatric Solid Tumors

October 2015 – AWOCCF grants $50,000 to Children’s Hospital of Philadelphia’s MATCH-NB Trial

April 2015 – The Truth 365 co-funds twelve research grants through A Collaborative Pediatric Cancer Research Awards Program totaling $600,000.

Here are the grant awardees:

Grant 1 – $50,000:

Dana-Farber Cancer Institute to support Dr. Xiaofeng Wang and his work on elucidating epigenetic mechanisms for therapeutic targeting in aggressive pediatric cancers; focusing on rhabdoid tumors, neuroblastoma and medulloblastoma.

Grant 2- $50,000:

MD Anderson Cancer Center to support Dr. Vidya Gopalakrishnan and her Phase I Immunotherapy Clinical Trial for recurrent pediatric brain tumors.

Grant 3 – $50,000:

Baylor College of Medicine to support Dr. Christopher DeRenzo’s project aimed at improving T-cell therapy for osteosarcoma.

Grant 4 – $50,000

Baylor College of Medicine to support Dr. Jason Yustein’s research aimed at dissecting and targeting the WNT pathway in metastatic osteosarcoma.

Grant 5 – $50,000:

Johns Hopkins University- School of Medicine to support Dr. David Loeb’s research aimed at circulating tumor DNA as a biomarker of metastasis in Ewing sarcoma.

Grant 6 – $50,000:

University of California San Francisco to support Kevin Shannon, MD in his research to test response and resistance to targeted and conventional agents in acute myeloid leukemia (AML).

Grant 7 – $50,000:

Memorial Sloan-Kettering Cancer Center to support Dr. Emily Slotkin’s research aimed at nucleic acid based therapeutics for the targeted treatment of Ewing sarcoma.

Grant 8 – $50,000:

Dana-Farber Cancer Institute to support Dr. Brian Crompton’s research aimed at targeting FAK and integrin signaling in preclinical models of Ewing sarcoma.

Grant 9 – $50,000:

Memorial Sloan Kettering Cancer Center to support Dr. Shakeel Modak’s Phase I Clinical Trial to study immuno-PET imaging of pediatric solid tumors using 124I-Humanized 3f8.

Grant 10 – $50,000:

Virginia Commonwealth University to support Dr. Anthony Faber in his research to test a novel and potent therapy for MYCN amplified neuroblastoma.



(Continued from previous column)

Grant 11 – $50,000:

University of Texas South Western Medical Center to support Dr. Theodore Laetsch’s research aimed at maximizing the therapeutic impact of CDK4/6 inhibition in rhabdomyosarcoma.

Grant 12 – $50,000

University of Alabama at Birmingham to support Dr. Gregory Friedman’s research aimed at targeting pediatric brain cancer with engineered Herpes Simplex Virus.

July 2014 – AWOCCF partners with Band of Parents to grant $400,000 to Children’s Hospital of Philadelphia’s MATCH-NB Trial

July 2014 – AWOCCF partners with Band of Parents to fully fund Phase I Study of Haploidentical Natural Killer Cells Plus Humanized 3f8 for $700,000 at Memorial Sloan-Kettering Cancer Center.

July 2014 – AWOCCF partners with Brooke’s Blossoming Hope Foundation to fund $30,000 trial at Texas A & M University – Corpus Christi, Texas under Dr. Magesh Thiyagarajan using Cold Atmospheric Plasma on neuroblastoma cells

July 2014 – AWOCCF grants $10,000 to Lucile Packard Children’s Hospital for DIPG research

June 2014– AWOCCF grants $80,000 toward Bi-Specific Antibody Therapy at MSKCC

May 2014 – The Truth 365 co-funds six research grants with the Rally Foundation for Childhood Cancer Research totaling $275,000.
Here are the grant awardees:

Grant 1 – $50,000:

UC San Francisco to support Kevin Shannon, MD in his research to test new treatments for pediatric acute myeloid leukemia (AML).
Leukemia is the most common childhood cancer with AML accounting for about20% of cases. In contrast to acute lymphoblastic leukemia (ALL), where 85-90% of children are now being cured, progress in AML has been much slower andtreatment protocols have not improved substantially since the 1980s. Dr. Shannon’s lab is investigating novel strategies for combining existing drugs with small molecules that target biochemical pathways that drive the growth of AML cells.

Grant 2- $50,000:

Dana-Farber Cancer Institute to support Dr. Cigall Kadoch and her work on chromatin regulation in pediatric sarcomas.
“We are most grateful for the support of Rally and The Truth 365 and are excited by the therapeutic implications of our recent work in this area,” said Dr. Kadoch. “These funds will be used to further develop our understanding of the mechanisms which underlie pediatric sarcomas such as synovial sarcoma.”



(Continued from previous column)

Grant 3- $50,000:

Baylor College of Medicine to support Dr. Christopher DeRenzo’s project aimed at harnessing the power of the body’s own immune system to treat pediatric solid tumors and brain tumors.

“Pediatric solid tumors and brain tumors contribute disproportionately to the morbidity and mortality of all children suffering from cancer, especially those with metastatic and/or recurrent disease,” said Dr. DeRenzo, at Baylor College of Medicine, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy. “This award supports my efforts aimed at developing a novel T-cell therapy, which targets a broad range of pediatric malignancies including osteosarcoma, neuroblastoma, glioblastoma, rhabdomyosarcoma, and Ewing’s sarcoma.”

Grant 4- $50,000:

Johns Hopkins Kimmel Cancer Center’s Division of Pediatric Oncology to support Don Small, M.D., Ph.D., and his research developing molecularly targeted therapy for FLT3 mutant pediatric acute myeloid leukemia.

“The money from this grant will enable us to carry out experiments to try to improve treatments for one of the most deadly pediatric leukemias, FLT3 mutant AML” said Don Small, M.D., Ph.D., Kyle Haydock Professor of Oncology and Pediatrics at the Sidney Kimmel Cancer Center at Johns Hopkins.

Grant 5 – $50,000:

City of Hope to support Saro Armenian, D.O., M.P.H., and his research to lower heart failure risk amongst childhood cancer survivors.

“Childhood cancer survivors are often at risk for many serious conditions – including heart failures – due to the cancer treatments they have received,” Armenian said. “With the support of Rally and The truth 365, my team and I can continue to investigate how to minimize this risk so they can lead healthy, productive lives well into adulthood.”

Grant #6 – $25,000:

Ann & Robert H. Lurie Children’s Hospital of Chicago to support Dr. Elizabeth J. Perlman’s project to analyze a molecular marker (1q gain) in Wilms tumors.

“Our goal, through the Children’s Oncology Group, is to identify molecular markers that will ensure that each child with Wilms tumor receives the appropriate therapy. Gain of chromosome 1q predicts relapse at all stages, and we would like to utilize this to guide therapy in future protocols,” said Dr. Perlman


November 2013 – AWOCCF partners with Band of Parents to fully fund the first in-human imaging of neuroblastoma and paraganglioma, MFBG, at MSKCC for $40,000.

May 2013 – AWOCCF funds Pediatric Oncology Profiling Program (POPP) entitled “Molecular Guided Therapy Program for Pediatric Cancers.” Led by Dr. Giselle Sholler of Helen DeVos Children’s Hospital, the POPP program is one of the first children’s programs with the capability of profiling the tumors of every child diagnosed or relapsed. AWOCCF’s investment of $60,000 is already helping 10 children who have enrolled in the trial.

February 2013 – AWOCCF funds new radioiodinated Hu3f8 antibody trial at Memorial Sloan Kettering. AWOCCF teamed with the I Back Jack Foundation to provide $130,000 for this promising new trial. Under the guidance of Dr. Shakeel Modak, this project will investigate radioiodinated Hu3f8 antibody and aid doctors in utilizing the antibody to maximum effectiveness in future trials and treatment protocols for children with solid tumors. There are currently 30 children enrolled in the trial.

November 2012 – Arms Wide Open and I BACK JACK commit $130,000 to fully fund the two-year PET Imaging of Solid Tumors using 124I-Humanized 3F8 Pilot Study for 30 childhood cancer patients at MSKCC – NYC.

June 2011 – Funded the first $150,000 of Children’s Hospital of Philadelphia’s $1.5 million Individualized Management of Pediatric Cancer Project.

January 2011 – AWOCCF granted $63,000 to fund the New Approaches to Neuroblastoma Therapy (NANT) trial using Oral Fenretinide LXS Powder in Recurrent or Resistant NB Patients, available in 14 hospitals in the U.S.

November 2010 – Granted $275,000 to Memorial Sloan-Kettering Cancer Center for further production and development of lgG1n.

November 2010 – Agreed to partner with four other non-profit childhood cancer foundations to fully fund the entire $1.5 million IgG1n antibody therapy.

January 2010 – Launch of the Arms Wide Open Neuroblastoma Initiatives Fund at Memorial Sloan-Kettering Cancer Center.

December 2009 – AWOCCF Granted $75,000 to Memorial Sloan-Kettering Cancer Center towards the humanized antibody therapy- IgG1n.